OPBK:NASDAQOP Bancorp Analysis
Data as of 2026-06-01 - not real-time
$14.06
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
OP Bancorp is trading at $14.06, just below its 20‑day SMA of $14.18 but comfortably above the 50‑day ($13.96) and 200‑day ($13.89) averages, indicating a lingering bullish bias. The RSI sits at 48.8, suggesting neutral momentum, while the MACD histogram is negative and the signal line is labeled bearish, hinting at short‑term downside pressure. Volume has been decreasing and 30‑day volatility is elevated at 26%, adding to near‑term uncertainty. Fundamentally, the stock appears deeply discounted: a trailing PE of 7.7 versus the industry average of 16.6 and a price‑to‑book of 0.92 support a value case. The dividend yield of 3.98% with a modest 26% payout ratio points to sustainable income. A DCF‑derived fair value of $32.79 implies more than 100% upside, though the model’s assumptions may be aggressive.
Revenue grew 12.3% year‑over‑year and operating margins are robust at 45.8%, underscoring strong profitability. The balance sheet is net‑cash positive, with $160M cash offsetting $111M debt, and a ROE of 12.3% reflects efficient capital use. The stock’s beta around 0.9 and a max drawdown of 17% signal moderate market sensitivity. Market sentiment is extremely bullish (Fear‑Greed Index 92.98), which could compress the upside window. The upcoming ex‑dividend date on May 7 adds a short‑term catalyst for dividend‑focused investors. Overall, the blend of attractive valuation, solid fundamentals, and a sustainable dividend suggests a buy‑and‑hold stance, with caution on near‑term technical weakness.
Revenue grew 12.3% year‑over‑year and operating margins are robust at 45.8%, underscoring strong profitability. The balance sheet is net‑cash positive, with $160M cash offsetting $111M debt, and a ROE of 12.3% reflects efficient capital use. The stock’s beta around 0.9 and a max drawdown of 17% signal moderate market sensitivity. Market sentiment is extremely bullish (Fear‑Greed Index 92.98), which could compress the upside window. The upcoming ex‑dividend date on May 7 adds a short‑term catalyst for dividend‑focused investors. Overall, the blend of attractive valuation, solid fundamentals, and a sustainable dividend suggests a buy‑and‑hold stance, with caution on near‑term technical weakness.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price hovering just above support at $13.58
- Bearish MACD momentum
- Decreasing volume and elevated volatility
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Significant valuation discount (PE 7.7 vs industry 16.6)
- Strong dividend yield of 3.98% with low payout ratio
- Robust earnings growth and operating margins
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF fair value suggesting >100% upside
- Sustainable cash‑flow generation and net‑cash position
- Stable dividend and solid ROE
Key Metrics & Analysis
Financial Health
Revenue Growth12.30%
Profit Margin29.13%
P/E Ratio7.7
ROE12.34%
ROA1.05%
P/B Ratio0.9
Op. Cash Flow$28.3M
Industry P/E16.6
Technical Analysis
TrendBullish
RSI48.8
Support$13.58
Resistance$14.85
MA 20$14.18
MA 50$13.96
MA 200$13.89
MACDBearish
VolumeDecreasing
Fear & Greed Index92.98
Valuation
Fair Value$32.79
Target Price$16.50
Upside/Downside17.35%
GradeUndervalued
TypeValue
Dividend Yield3.98%
Risk Assessment
Beta0.92
Volatility26.15%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.